TGF-α and IL-6 plasma levels selectively identify CML patients who fail to achieve an early molecular response or progress in the first year of therapy

Versatile functions for IL-6 in metabolism and cancer

(2015) Jan Mauer et al.   TRENDS IN IMMUNOLOGY

Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline

(2014) S. Branford et al.   BLOOD

TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets

(2014) D. T. Yeung et al.   BLOOD

Cancer-related inflammation and treatment effectiveness

(2014) Connie I Diakos et al.   LANCET ONCOLOGY

The tumor microenvironment is the main source of IL-6 for plasma cell tumor development in mice

(2014) T R Rosean et al.   LEUKEMIA

A ‘telomere-associated secretory phenotype’ cooperates with BCR-ABL to drive malignant proliferation of leukemic cells

(2014) M Braig et al.   LEUKEMIA

EGFR has a tumour-promoting role in liver macrophages during hepatocellular carcinoma formation

(2014) Hanane Lanaya et al.   NATURE CELL BIOLOGY

Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib

(2013) T. P. Hughes et al.   BLOOD

Autocrine TNF-  production supports CML stem and progenitor cell survival and enhances their proliferation

(2013) P. Gallipoli et al.   BLOOD

Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML

(2013) S. Branford et al.   BLOOD

Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt- -catenin signaling

(2013) B. Zhang et al.   BLOOD

Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib

(2012) D. Marin et al.   BLOOD

HIF1  is required for survival maintenance of chronic myeloid leukemia stem cells

(2012) H. Zhang et al.   BLOOD

Altered Microenvironmental Regulation of Leukemic and Normal Stem Cells in Chronic Myelogenous Leukemia

(2012) Bin Zhang et al.   CANCER CELL

Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)

(2012) B Hanfstein et al.   LEUKEMIA

Mesenchymal stem cells promote growth and angiogenesis of tumors in mice

(2012) W-H Huang et al.   ONCOGENE

IL-6 Controls Leukemic Multipotent Progenitor Cell Fate and Contributes to Chronic Myelogenous Leukemia Development

(2011) Damien Reynaud et al.   CANCER CELL

Loss or Inhibition of Stromal-Derived PlGF Prolongs Survival of Mice with Imatinib-Resistant Bcr-Abl1+ Leukemia

(2011) Thomas Schmidt et al.   CANCER CELL

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

Circulating Interleukin (IL)-8, IL-2R, IL-12, and IL-15 Levels Are Independently Prognostic in Primary Myelofibrosis: A Comprehensive Cytokine Profiling Study

(2011) Ayalew Tefferi et al.   JOURNAL OF CLINICAL ONCOLOGY

Leukemia Stem Cells and Microenvironment: Biology and Therapeutic Targeting

(2011) Marina Y. Konopleva et al.   JOURNAL OF CLINICAL ONCOLOGY

Assessment of BCR-ABL1 Transcript Levels at 3 Months Is the Only Requirement for Predicting Outcome for Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors

(2011) David Marin et al.   JOURNAL OF CLINICAL ONCOLOGY

IPSS-independent prognostic value of plasma CXCL10, IL-7 and IL-6 levels in myelodysplastic syndromes

(2011) A Pardanani et al.   LEUKEMIA

Chronic Myeloid Leukemia Patients in Prolonged Remission following Interferon-α Monotherapy Have Distinct Cytokine and Oligoclonal Lymphocyte Profile

(2011) Anna Kreutzman et al.   PLoS One

Recurrent expression signatures of cytokines and chemokines are present and are independently prognostic in acute myelogenous leukemia and myelodysplasia

(2010) S. M. Kornblau et al.   BLOOD

Plasma Transforming Growth Factor α and Amphiregulin Protein Levels in NCIC Clinical Trials Group BR.21

(2010) Christina L. Addison et al.   JOURNAL OF CLINICAL ONCOLOGY

TGF-β–FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia

(2010) Kazuhito Naka et al.   NATURE

Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

(2010) Hagop Kantarjian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia

(2010) Giuseppe Saglio et al.   NEW ENGLAND JOURNAL OF MEDICINE

Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia

(2009) A Hochhaus et al.   LEUKEMIA

Differential Effects of EGFR Ligands on Endocytic Sorting of the Receptor

(2009) Kirstine Roepstorff et al.   TRAFFIC

Clinical significance of pretreatment serum amphiregulin and transforming growth factor-α, and an epidermal growth factor receptor somatic mutation in patients with advanced non-squamous, non-small cell lung cancer

(2008) Katsuhiro Masago et al.   CANCER SCIENCE

Increased bone marrow microvascular density in haematological malignancies is associated with differential regulation of angiogenic factors

(2008) H F S Negaard et al.   LEUKEMIA

The chemokine interleukin-8 and the surface activation protein CD69 are markers for Bcr-Abl activity in chronic myeloid leukemia

(2008) Oliver Hantschel et al.   Molecular Oncology

Cancer-related inflammation

(2008) Alberto Mantovani et al.   NATURE